BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] gained 11.29% on the last trading session, reaching $11.34 price per share at the time. The company report on April 14, 2021 that BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema.
—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan—.
—NHI price listing triggers $15 million milestone payment to BioCryst—.
BioCryst Pharmaceuticals Inc. represents 176.69 million in outstanding shares, while the company has a total market value of $2.05 billion with the latest information. BCRX stock price has been found in the range of $10.13 to $11.58.
If compared to the average trading volume of 7.12M shares, BCRX reached a trading volume of 8470181 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $14.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 29, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.86, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 114.98.
Trading performance analysis for BCRX stock
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.04. With this latest performance, BCRX shares dropped by -12.84% in over the last four-week period, additionally plugging by 190.03% over the last 6 months – not to mention a rise of 320.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 55.68, with the RSI for the last a single of trading hit 61.39, and the three-weeks RSI is set at 54.09 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 10.97, while it was recorded at 10.19 for the last single week of trading, and 6.70 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.10.
BioCryst Pharmaceuticals Inc. [BCRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
An analysis of insider ownership at BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $1,227 million, or 69.20% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,259,745, which is approximately 1.981% of the company’s market cap and around 0.80% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,695,818 shares of the stock with an approximate value of $129.37 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $118.2 million in BCRX stock with ownership of nearly 1.013% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 97 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 19,424,230 shares. Additionally, 71 investors decreased positions by around 25,463,148 shares, while 23 investors held positions by with 75,572,208 shares. The mentioned changes placed institutional holdings at 120,459,586 shares, according to the latest SEC report filing. BCRX stock had 38 new institutional investments in for a total of 6,833,232 shares, while 15 institutional investors sold positions of 2,990,859 shares during the same period.